Analyst Joanna Gajuk of Bank of America Securities reiterated a Buy rating on HCA Healthcare (HCA – Research Report), retaining the price target of $370.00.
Joanna Gajuk’s rating is based on HCA Healthcare’s strong position relative to its peers amidst political uncertainties, particularly regarding potential Medicaid cuts. The company is confident in its ability to navigate these changes more effectively than the average hospital, which supports the Buy rating.
Additionally, HCA Healthcare is experiencing above-average volume growth, driven by robust exchange enrollment and favorable payor mix trends in its markets. The company’s strategic investments in both inpatient and outpatient capacity further bolster its growth prospects, making it a compelling investment opportunity despite the broader industry’s volatility.
In another report released on March 5, TD Cowen also maintained a Buy rating on the stock with a $377.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HCA in relation to earlier this year.